| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 64 | 2025 | 355 | 17.330 |
Why?
|
| Esophageal Neoplasms | 60 | 2025 | 387 | 16.380 |
Why?
|
| Adenocarcinoma | 57 | 2025 | 1014 | 12.460 |
Why?
|
| Stomach Neoplasms | 18 | 2024 | 566 | 7.240 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 22 | 2025 | 417 | 6.980 |
Why?
|
| Liver Neoplasms | 31 | 2024 | 1381 | 6.120 |
Why?
|
| Carcinoma, Hepatocellular | 28 | 2024 | 985 | 6.070 |
Why?
|
| Precancerous Conditions | 13 | 2025 | 280 | 4.560 |
Why?
|
| Alcohol Drinking | 11 | 2024 | 358 | 4.450 |
Why?
|
| Helicobacter Infections | 17 | 2024 | 1278 | 4.390 |
Why?
|
| Gastroesophageal Reflux | 20 | 2024 | 339 | 3.910 |
Why?
|
| Liver Cirrhosis | 20 | 2025 | 898 | 3.680 |
Why?
|
| Risk Factors | 88 | 2025 | 10941 | 3.540 |
Why?
|
| Helicobacter pylori | 16 | 2024 | 1336 | 3.470 |
Why?
|
| Middle Aged | 116 | 2025 | 28964 | 2.790 |
Why?
|
| Incidence | 45 | 2025 | 3380 | 2.740 |
Why?
|
| Obesity | 22 | 2024 | 2391 | 2.650 |
Why?
|
| Aged | 92 | 2025 | 21406 | 2.530 |
Why?
|
| Humans | 206 | 2025 | 132061 | 2.330 |
Why?
|
| Colorectal Neoplasms | 11 | 2024 | 632 | 2.270 |
Why?
|
| Male | 133 | 2025 | 64922 | 2.140 |
Why?
|
| Early Detection of Cancer | 8 | 2024 | 414 | 2.140 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 261 | 2.120 |
Why?
|
| United States | 47 | 2025 | 11658 | 2.040 |
Why?
|
| Smoking | 11 | 2023 | 938 | 2.000 |
Why?
|
| Life Style | 7 | 2022 | 450 | 1.980 |
Why?
|
| Female | 131 | 2025 | 70712 | 1.970 |
Why?
|
| Veterans | 17 | 2025 | 1757 | 1.850 |
Why?
|
| Neoplasms | 9 | 2024 | 2954 | 1.850 |
Why?
|
| Adult | 74 | 2025 | 31568 | 1.770 |
Why?
|
| Case-Control Studies | 33 | 2021 | 3418 | 1.750 |
Why?
|
| Risk Assessment | 31 | 2025 | 3736 | 1.740 |
Why?
|
| Proton Pump Inhibitors | 9 | 2023 | 282 | 1.670 |
Why?
|
| Mendelian Randomization Analysis | 9 | 2021 | 98 | 1.610 |
Why?
|
| Health Status Disparities | 6 | 2024 | 256 | 1.550 |
Why?
|
| Cross-Sectional Studies | 24 | 2023 | 3761 | 1.490 |
Why?
|
| Metaplasia | 11 | 2022 | 217 | 1.440 |
Why?
|
| Demography | 6 | 2021 | 240 | 1.410 |
Why?
|
| Prevalence | 22 | 2025 | 2658 | 1.410 |
Why?
|
| Population Surveillance | 5 | 2022 | 415 | 1.370 |
Why?
|
| Esophagoscopy | 7 | 2025 | 168 | 1.330 |
Why?
|
| Histamine H2 Antagonists | 3 | 2019 | 49 | 1.320 |
Why?
|
| Registries | 17 | 2024 | 1572 | 1.290 |
Why?
|
| Odds Ratio | 15 | 2021 | 1253 | 1.290 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 7102 | 1.280 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 743 | 1.280 |
Why?
|
| Texas | 19 | 2025 | 3629 | 1.260 |
Why?
|
| Stomach | 2 | 2022 | 273 | 1.170 |
Why?
|
| Veterans Health | 2 | 2020 | 174 | 1.160 |
Why?
|
| Socioeconomic Factors | 9 | 2024 | 898 | 1.150 |
Why?
|
| Logistic Models | 16 | 2021 | 1838 | 1.150 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2022 | 2849 | 1.140 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 767 | 1.140 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 487 | 1.110 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 81 | 1.080 |
Why?
|
| Body Mass Index | 9 | 2024 | 1694 | 1.060 |
Why?
|
| Models, Statistical | 3 | 2016 | 492 | 1.060 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 13 | 1.050 |
Why?
|
| Colonic Polyps | 3 | 2023 | 85 | 1.050 |
Why?
|
| Intestines | 3 | 2021 | 603 | 1.050 |
Why?
|
| Nutrition Surveys | 7 | 2022 | 314 | 1.020 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 309 | 1.010 |
Why?
|
| Mexican Americans | 2 | 2018 | 167 | 1.000 |
Why?
|
| Body Height | 4 | 2018 | 204 | 0.980 |
Why?
|
| Pancreatic Neoplasms | 2 | 2024 | 729 | 0.980 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 305 | 0.970 |
Why?
|
| Disease Progression | 13 | 2025 | 2224 | 0.960 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 263 | 0.960 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2024 | 142 | 0.930 |
Why?
|
| Cohort Studies | 21 | 2024 | 5164 | 0.930 |
Why?
|
| Global Health | 5 | 2022 | 643 | 0.930 |
Why?
|
| Endoscopy, Digestive System | 7 | 2025 | 158 | 0.930 |
Why?
|
| Anthropometry | 2 | 2017 | 194 | 0.900 |
Why?
|
| Rural Population | 3 | 2024 | 240 | 0.890 |
Why?
|
| Aspirin | 3 | 2016 | 220 | 0.880 |
Why?
|
| Primary Health Care | 5 | 2025 | 791 | 0.870 |
Why?
|
| Hepatitis C | 3 | 2023 | 386 | 0.870 |
Why?
|
| Esophagogastric Junction | 2 | 2016 | 34 | 0.870 |
Why?
|
| Predictive Value of Tests | 13 | 2025 | 2320 | 0.850 |
Why?
|
| Specimen Handling | 1 | 2024 | 149 | 0.840 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 370 | 0.800 |
Why?
|
| Leptin | 2 | 2015 | 219 | 0.800 |
Why?
|
| Young Adult | 24 | 2024 | 9957 | 0.800 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 3350 | 0.790 |
Why?
|
| Self Care | 1 | 2024 | 226 | 0.790 |
Why?
|
| SEER Program | 6 | 2024 | 219 | 0.770 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2023 | 240 | 0.770 |
Why?
|
| Gallbladder Neoplasms | 1 | 2022 | 15 | 0.750 |
Why?
|
| Prognosis | 13 | 2024 | 5009 | 0.740 |
Why?
|
| Urban Population | 1 | 2023 | 244 | 0.720 |
Why?
|
| Minority Groups | 2 | 2020 | 249 | 0.720 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 20 | 0.710 |
Why?
|
| Liver Transplantation | 4 | 2025 | 1103 | 0.710 |
Why?
|
| Retrospective Studies | 28 | 2025 | 17419 | 0.700 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 480 | 0.660 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 33 | 0.650 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 385 | 0.640 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2021 | 688 | 0.630 |
Why?
|
| Electric Impedance | 2 | 2017 | 73 | 0.630 |
Why?
|
| Stomach Diseases | 1 | 2020 | 56 | 0.630 |
Why?
|
| Electronic Health Records | 4 | 2024 | 800 | 0.600 |
Why?
|
| Obesity, Abdominal | 2 | 2016 | 41 | 0.600 |
Why?
|
| Diet | 5 | 2023 | 1124 | 0.590 |
Why?
|
| Endoscopic Mucosal Resection | 3 | 2024 | 79 | 0.550 |
Why?
|
| Virus Diseases | 1 | 2020 | 289 | 0.550 |
Why?
|
| Klatskin Tumor | 1 | 2017 | 6 | 0.540 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5409 | 0.540 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 105 | 0.520 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1170 | 0.510 |
Why?
|
| Prospective Studies | 16 | 2024 | 6567 | 0.500 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 1436 | 0.500 |
Why?
|
| Acculturation | 1 | 2016 | 63 | 0.490 |
Why?
|
| Overweight | 3 | 2023 | 383 | 0.490 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 364 | 0.490 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 84 | 0.490 |
Why?
|
| Fibrosis | 3 | 2022 | 423 | 0.490 |
Why?
|
| Tea | 1 | 2015 | 18 | 0.480 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 124 | 0.480 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 123 | 0.480 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 1828 | 0.480 |
Why?
|
| Survival Analysis | 7 | 2019 | 1573 | 0.480 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 223 | 0.480 |
Why?
|
| Coffee | 1 | 2015 | 30 | 0.480 |
Why?
|
| Cold Temperature | 1 | 2015 | 84 | 0.470 |
Why?
|
| Environmental Exposure | 1 | 2018 | 234 | 0.470 |
Why?
|
| Serum | 1 | 2015 | 43 | 0.470 |
Why?
|
| Hot Temperature | 1 | 2015 | 141 | 0.460 |
Why?
|
| Exercise | 4 | 2022 | 857 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 897 | 0.450 |
Why?
|
| Adipokines | 1 | 2015 | 77 | 0.450 |
Why?
|
| Adiponectin | 1 | 2015 | 128 | 0.450 |
Why?
|
| Europe | 6 | 2024 | 372 | 0.450 |
Why?
|
| Chemoprevention | 1 | 2015 | 53 | 0.450 |
Why?
|
| Models, Genetic | 1 | 2017 | 771 | 0.440 |
Why?
|
| Cost of Illness | 1 | 2016 | 283 | 0.440 |
Why?
|
| Biopsy | 4 | 2022 | 1284 | 0.430 |
Why?
|
| Adipose Tissue | 1 | 2017 | 504 | 0.430 |
Why?
|
| Melatonin | 1 | 2014 | 30 | 0.430 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 637 | 0.420 |
Why?
|
| Australia | 7 | 2017 | 185 | 0.420 |
Why?
|
| Birth Weight | 1 | 2015 | 350 | 0.420 |
Why?
|
| Survival Rate | 4 | 2024 | 2192 | 0.410 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 162 | 0.410 |
Why?
|
| Acyltransferases | 2 | 2024 | 45 | 0.410 |
Why?
|
| Age Factors | 7 | 2020 | 2912 | 0.400 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 1454 | 0.400 |
Why?
|
| Risk | 7 | 2020 | 760 | 0.390 |
Why?
|
| Melanoma | 1 | 2020 | 951 | 0.390 |
Why?
|
| ROC Curve | 5 | 2021 | 601 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 357 | 0.380 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 59 | 0.380 |
Why?
|
| Adiposity | 1 | 2014 | 207 | 0.380 |
Why?
|
| Algorithms | 3 | 2022 | 1728 | 0.380 |
Why?
|
| Liver Diseases | 1 | 2016 | 384 | 0.380 |
Why?
|
| Age Distribution | 4 | 2022 | 437 | 0.370 |
Why?
|
| Mortality | 2 | 2024 | 268 | 0.370 |
Why?
|
| Sex Factors | 8 | 2020 | 1353 | 0.370 |
Why?
|
| Inflammation | 2 | 2018 | 1517 | 0.360 |
Why?
|
| Premature Birth | 1 | 2015 | 419 | 0.350 |
Why?
|
| HIV Infections | 3 | 2019 | 2035 | 0.340 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2011 | 79 | 0.330 |
Why?
|
| Acetaminophen | 1 | 2011 | 97 | 0.330 |
Why?
|
| Insulin | 1 | 2015 | 1168 | 0.330 |
Why?
|
| Guideline Adherence | 2 | 2024 | 393 | 0.330 |
Why?
|
| Time Factors | 7 | 2020 | 6448 | 0.320 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 1356 | 0.320 |
Why?
|
| Colonoscopy | 3 | 2023 | 252 | 0.310 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 204 | 0.310 |
Why?
|
| United Kingdom | 6 | 2019 | 235 | 0.310 |
Why?
|
| Biomarkers | 2 | 2020 | 3406 | 0.300 |
Why?
|
| Cytokines | 2 | 2016 | 1358 | 0.290 |
Why?
|
| Area Under Curve | 4 | 2021 | 321 | 0.290 |
Why?
|
| Vitamin D | 2 | 2021 | 183 | 0.280 |
Why?
|
| Adolescent | 14 | 2021 | 20562 | 0.280 |
Why?
|
| Sarcopenia | 2 | 2025 | 57 | 0.270 |
Why?
|
| Meta-Analysis as Topic | 3 | 2024 | 172 | 0.270 |
Why?
|
| Databases, Factual | 4 | 2021 | 1227 | 0.270 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 134 | 0.270 |
Why?
|
| Lipase | 2 | 2024 | 97 | 0.260 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 84 | 0.250 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 3091 | 0.250 |
Why?
|
| Confidence Intervals | 2 | 2019 | 276 | 0.240 |
Why?
|
| Hyperplasia | 2 | 2022 | 195 | 0.230 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 368 | 0.230 |
Why?
|
| Recurrence | 4 | 2018 | 1470 | 0.230 |
Why?
|
| Gastritis | 2 | 2019 | 373 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1297 | 0.230 |
Why?
|
| Ablation Techniques | 2 | 2024 | 31 | 0.220 |
Why?
|
| Critical Pathways | 1 | 2025 | 75 | 0.220 |
Why?
|
| Hospitals, Urban | 1 | 2024 | 97 | 0.220 |
Why?
|
| Genotype | 3 | 2022 | 2697 | 0.220 |
Why?
|
| Residence Characteristics | 2 | 2024 | 286 | 0.220 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 19 | 0.200 |
Why?
|
| Gastrectomy | 1 | 2024 | 102 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2018 | 462 | 0.200 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1658 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2025 | 3142 | 0.190 |
Why?
|
| Arsenic | 1 | 2023 | 48 | 0.190 |
Why?
|
| Frailty | 1 | 2024 | 136 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 255 | 0.190 |
Why?
|
| Hospitals, Veterans | 3 | 2018 | 345 | 0.180 |
Why?
|
| Natural Language Processing | 1 | 2022 | 74 | 0.180 |
Why?
|
| Social Class | 1 | 2023 | 204 | 0.180 |
Why?
|
| Gastric Mucosa | 2 | 2022 | 491 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 346 | 0.180 |
Why?
|
| Esophagitis, Peptic | 1 | 2021 | 37 | 0.180 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 59 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2023 | 200 | 0.170 |
Why?
|
| Physical Fitness | 1 | 2021 | 91 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 157 | 0.170 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 158 | 0.170 |
Why?
|
| Medicare | 2 | 2022 | 448 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 3014 | 0.170 |
Why?
|
| North America | 2 | 2019 | 264 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1408 | 0.160 |
Why?
|
| Hepacivirus | 1 | 2022 | 272 | 0.160 |
Why?
|
| Diet Records | 1 | 2020 | 71 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2024 | 1450 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2020 | 82 | 0.160 |
Why?
|
| Dietary Fiber | 1 | 2020 | 79 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2021 | 172 | 0.160 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 129 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 88 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2020 | 108 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1095 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1301 | 0.150 |
Why?
|
| Cholesterol | 1 | 2002 | 558 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1610 | 0.150 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 3990 | 0.150 |
Why?
|
| Gastroenterology | 2 | 2024 | 212 | 0.150 |
Why?
|
| Safety-net Providers | 1 | 2020 | 70 | 0.150 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 27 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 231 | 0.150 |
Why?
|
| Fruit | 1 | 2020 | 234 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 136 | 0.150 |
Why?
|
| Self Report | 2 | 2018 | 549 | 0.140 |
Why?
|
| Gastric Acid | 1 | 2018 | 55 | 0.140 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 20 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2146 | 0.140 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 62 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 313 | 0.140 |
Why?
|
| Omeprazole | 1 | 2018 | 101 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 131 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2023 | 721 | 0.140 |
Why?
|
| Sex Distribution | 2 | 2016 | 328 | 0.140 |
Why?
|
| Software | 1 | 2022 | 732 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2019 | 792 | 0.130 |
Why?
|
| Energy Intake | 1 | 2020 | 493 | 0.130 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 146 | 0.130 |
Why?
|
| Liver | 2 | 2021 | 1797 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 42 | 0.130 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 19 | 0.130 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 167 | 0.130 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 89 | 0.130 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2016 | 28 | 0.130 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 50 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 824 | 0.120 |
Why?
|
| Cause of Death | 1 | 2019 | 510 | 0.120 |
Why?
|
| Protective Factors | 1 | 2016 | 90 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 235 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 237 | 0.120 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 142 | 0.120 |
Why?
|
| Keratinocytes | 1 | 2016 | 62 | 0.120 |
Why?
|
| Duodenum | 1 | 2016 | 113 | 0.120 |
Why?
|
| Celiac Disease | 1 | 2016 | 73 | 0.120 |
Why?
|
| Comorbidity | 1 | 2021 | 1609 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 86 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2018 | 472 | 0.120 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2016 | 68 | 0.120 |
Why?
|
| Geography | 3 | 2020 | 123 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2018 | 300 | 0.110 |
Why?
|
| Schistosoma japonicum | 2 | 2012 | 10 | 0.110 |
Why?
|
| Apgar Score | 1 | 2014 | 49 | 0.110 |
Why?
|
| Alcoholic Beverages | 1 | 2014 | 18 | 0.110 |
Why?
|
| Hypertension | 2 | 2021 | 1396 | 0.110 |
Why?
|
| Hernia, Hiatal | 1 | 2014 | 60 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2024 | 13028 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 697 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 413 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 347 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 327 | 0.100 |
Why?
|
| Policy Making | 1 | 2013 | 62 | 0.100 |
Why?
|
| Cohort Effect | 1 | 2012 | 5 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 588 | 0.100 |
Why?
|
| Sweden | 1 | 2012 | 57 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 239 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 305 | 0.090 |
Why?
|
| Body Weight | 1 | 2016 | 994 | 0.090 |
Why?
|
| Schistosomiasis | 1 | 2012 | 54 | 0.090 |
Why?
|
| New South Wales | 1 | 2011 | 12 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 993 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 234 | 0.090 |
Why?
|
| Beer | 1 | 2011 | 5 | 0.090 |
Why?
|
| Age of Onset | 1 | 2013 | 621 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2017 | 554 | 0.090 |
Why?
|
| Schistosomiasis japonica | 1 | 2011 | 6 | 0.090 |
Why?
|
| Wine | 1 | 2011 | 16 | 0.090 |
Why?
|
| Cattle Diseases | 1 | 2011 | 22 | 0.090 |
Why?
|
| Phenotype | 2 | 2018 | 4529 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 921 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 822 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 737 | 0.080 |
Why?
|
| Computer Terminals | 1 | 2010 | 2 | 0.080 |
Why?
|
| Sex Characteristics | 2 | 2023 | 327 | 0.080 |
Why?
|
| Pregnancy | 2 | 2014 | 7566 | 0.080 |
Why?
|
| Mutation | 1 | 2024 | 6229 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 1067 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 2011 | 406 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 139 | 0.070 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 172 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 700 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1247 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 662 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 2172 | 0.060 |
Why?
|
| Child | 5 | 2021 | 25789 | 0.050 |
Why?
|
| Geography, Medical | 1 | 2023 | 18 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2024 | 117 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 23 | 0.050 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 40 | 0.050 |
Why?
|
| Phospholipases | 1 | 2022 | 6 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 430 | 0.050 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 191 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2022 | 39 | 0.050 |
Why?
|
| Sentinel Surveillance | 2 | 2012 | 24 | 0.050 |
Why?
|
| Praziquantel | 2 | 2012 | 12 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 307 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2023 | 211 | 0.040 |
Why?
|
| Anthelmintics | 2 | 2012 | 55 | 0.040 |
Why?
|
| Sunburn | 1 | 2021 | 4 | 0.040 |
Why?
|
| Specialties, Nursing | 1 | 2001 | 4 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2025 | 568 | 0.040 |
Why?
|
| Pigmentation | 1 | 2021 | 36 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 25 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 38 | 0.040 |
Why?
|
| Cattle | 2 | 2012 | 569 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 491 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 305 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 188 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1379 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 91 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 78 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2020 | 232 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 398 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 316 | 0.040 |
Why?
|
| Neurology | 1 | 2001 | 117 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 359 | 0.040 |
Why?
|
| Causality | 1 | 2018 | 94 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 98 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 195 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1033 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 256 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 295 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 332 | 0.030 |
Why?
|
| Weight Loss | 1 | 2021 | 515 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 2092 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 142 | 0.030 |
Why?
|
| Aftercare | 1 | 2018 | 155 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1491 | 0.030 |
Why?
|
| Learning Curve | 1 | 2017 | 57 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 322 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1131 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2016 | 68 | 0.030 |
Why?
|
| Queensland | 1 | 2016 | 5 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 114 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 604 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 141 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 141 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 697 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 161 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 233 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2016 | 218 | 0.030 |
Why?
|
| Colon | 1 | 2017 | 370 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 617 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 454 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2018 | 14751 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 324 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1994 | 119 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 830 | 0.020 |
Why?
|
| Stroke | 1 | 2001 | 1085 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1694 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 87 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 803 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1686 | 0.020 |
Why?
|
| China | 1 | 2012 | 290 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 62 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 95 | 0.020 |
Why?
|
| Television | 1 | 2010 | 71 | 0.020 |
Why?
|
| Puberty | 1 | 2010 | 104 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 34882 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8549 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 4703 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13064 | 0.010 |
Why?
|
| Community Health Services | 1 | 2001 | 92 | 0.010 |
Why?
|
| Acute Disease | 1 | 1994 | 1160 | 0.010 |
Why?
|